Market Closed -
Nasdaq
04:30:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
0.6798
USD
|
-2.90%
|
|
-2.90%
|
-5.58%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
316
|
76.54
|
29.42
|
19.52
|
18.43
|
-
|
-
|
Enterprise Value (EV)
1 |
152.4
|
13.98
|
-3.368
|
19.52
|
0.3312
|
-53.27
|
-90.87
|
P/E ratio
|
-1.64
x
|
-1.48
x
|
-0.47
x
|
-0.5
x
|
-0.56
x
|
-0.37
x
|
-0.33
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-4,557,111
x
|
-269,964
x
|
55,467
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-3,990,022
x
|
-266,135
x
|
78,089
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
0%
|
-
|
-
|
-
|
-
|
Price to Book
|
1.91
x
|
0.65
x
|
0.47
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
25,261
|
25,262
|
25,581
|
27,113
|
27,113
|
-
|
-
|
Reference price
2 |
12.51
|
3.030
|
1.150
|
0.7200
|
0.6798
|
0.6798
|
0.6798
|
Announcement Date
|
3/29/21
|
2/17/22
|
3/9/23
|
3/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-33.45
|
-51.79
|
-60.72
|
-
|
-
|
-
|
-
|
EBIT
1 |
-38.97
|
-33.64
|
-52.23
|
-61.21
|
-39.9
|
-34.01
|
-74.72
|
-85.7
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-34.84
|
-51.75
|
-61.62
|
-38.35
|
-33.67
|
-74.72
|
-85.7
|
Net income
1 |
-
|
-34.84
|
-51.75
|
-61.62
|
-38.35
|
-32.68
|
-52.41
|
-65.65
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-420.7
|
-7.620
|
-2.050
|
-2.430
|
-1.440
|
-1.203
|
-1.815
|
-2.075
|
Free Cash Flow
|
-
|
-38.2
|
-52.53
|
-43.13
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/2/20
|
3/29/21
|
2/17/22
|
3/9/23
|
3/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-13.36
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-13.47
|
-
|
-17.12
|
-13.62
|
-13.52
|
-13.49
|
-11.16
|
-5.855
|
-6.671
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-13.41
|
-
|
-
|
-
|
-
|
-12.99
|
-10.74
|
-8.136
|
-6.475
|
-
|
-
|
-
|
-
|
Net income
1 |
-13.41
|
-16.94
|
-16.89
|
-13.73
|
-14.07
|
-12.99
|
-10.74
|
-8.136
|
-6.475
|
-5.477
|
-10.5
|
-4.8
|
-4.3
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.5300
|
-0.6700
|
-0.6700
|
-0.5400
|
-0.5500
|
-0.5100
|
-0.4100
|
-0.3000
|
-0.2300
|
-0.2000
|
-0.2500
|
-0.1350
|
-0.1150
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/17/22
|
4/29/22
|
7/29/22
|
11/8/22
|
3/9/23
|
4/28/23
|
7/31/23
|
11/6/23
|
3/8/24
|
4/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
164
|
62.6
|
32.8
|
-
|
18.1
|
71.7
|
109
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-38.2
|
-52.5
|
-43.1
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-73.9%
|
-36.6%
|
-68.9%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
6.550
|
4.640
|
2.430
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-8.350
|
-2.070
|
-1.690
|
-
|
-
|
-
|
-
|
Capex
|
-
|
0.22
|
0.2
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/29/21
|
2/17/22
|
3/9/23
|
3/8/24
|
-
|
-
|
-
|
Last Close Price
0.6798
USD Average target price
6
USD Spread / Average Target +782.61% Consensus |
1st Jan change
|
Capi.
|
---|
| -5.58% | 18.43M | | +3.91% | 109B | | +10.87% | 105B | | +1.28% | 22.25B | | -13.14% | 22.09B | | -7.05% | 18.68B | | -38.36% | 17.58B | | -10.66% | 16.85B | | +3.75% | 13.76B | | +36.70% | 12.46B |
Bio Therapeutic Drugs
|